Literature DB >> 11020235

Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.

J Shen1, A Benedict Gomes, A Gallagher, K Stafford, B C Yoburn.   

Abstract

Studies suggest that acute and chronic opioids can regulate the cAMP-dependent protein kinase (PKA) signaling pathway and that changes in this pathway may be involved in opioid tolerance. In the present study, we examined the role of cAMP-PKA on mu-opioid receptor downregulation and tolerance in mice. Mice were injected intracerebroventricular (i.c.v.) and intrathecal (i.t.) once a day with an antisense oligodeoxynucleotide directed at the mRNA for the alpha catalytic subunit of mouse PKA. Controls were treated with saline or a mismatch oligodeoxynucleotide. On day 2 of treatment, mice were implanted s.c. with a 25-mg morphine pellet and an osmotic minipump infusing morphine (40 mg/kg/day) for 3 days. Other mice were implanted with an osmotic minipump infusing etorphine (125, 250 microg/kg/day) for 2 days. Control mice were implanted s.c. with inert placebo pellets. At the end of treatment, pumps and pellets were removed and mice tested for morphine or etorphine analgesia. Other mice were sacrificed and mu-opioid receptor binding assays conducted in whole brain. Both infusion doses of etorphine produced significant tolerance (ED(50) shift = 3.6 and 6.3-fold). The higher etorphine infusion produced downregulation of mu-receptor density ( approximately 30%) while the lower infusion dose of etorphine did not. Morphine treatment also produced significant tolerance in mice (ED(50) shift = 4.5-fold), but no receptor downregulation. Antisense to PKA partially blocked tolerance induced by the higher dose of etorphine, but had no effect on receptor downregulation. On the other hand, antisense to PKA completely blocked tolerance induced by morphine and the lower infusion dose of etorphine. The mismatch oligodeoxynucleotide had no effect on any measure. These results suggest that PKA has a limited role in opioid agonist-induced receptor downregulation. However, the partial block of tolerance for the high infusion dose of etorphine and the complete block of tolerance for morphine and the low infusion dose of etorphine suggests that PKA may play a critical role in tolerance that is "receptor-regulation-independent." Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11020235     DOI: 10.1002/1098-2396(20001201)38:3<322::AID-SYN11>3.0.CO;2-1

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  14 in total

1.  A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia.

Authors:  Kassi Psifogeorgou; Kassi Psigfogeorgou; Dimitra Terzi; Maria Martha Papachatzaki; Artemis Varidaki; Deveroux Ferguson; Stephen J Gold; Venetia Zachariou
Journal:  J Neurosci       Date:  2011-04-13       Impact factor: 6.167

2.  Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation.

Authors:  Chad E Groer; Cullen L Schmid; Alex M Jaeger; Laura M Bohn
Journal:  J Biol Chem       Date:  2011-07-14       Impact factor: 5.157

3.  Long-term morphine treatment decreases the association of mu-opioid receptor (MOR1) mRNA with polysomes through miRNA23b.

Authors:  Qifang Wu; Lei Zhang; Ping-Yee Law; Li-Na Wei; Horace H Loh
Journal:  Mol Pharmacol       Date:  2009-01-14       Impact factor: 4.436

Review 4.  Protein kinases and addiction.

Authors:  Anna M Lee; Robert O Messing
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

5.  Pre-treatment with a PKC or PKA inhibitor prevents the development of morphine tolerance but not physical dependence in mice.

Authors:  Bichoy H Gabra; Chris P Bailey; Eamonn Kelly; Forrest L Smith; Graeme Henderson; William L Dewey
Journal:  Brain Res       Date:  2008-04-24       Impact factor: 3.252

6.  Phosphorylation of unique C-terminal sites of the mu-opioid receptor variants 1B2 and 1C1 influences their Gs association following chronic morphine.

Authors:  Sumita Chakrabarti; Nai-Jiang Liu; Alan R Gintzler
Journal:  J Neurochem       Date:  2019-10-20       Impact factor: 5.372

7.  Role of kappa and delta opioid receptors in mediating morphine-induced antinociception in morphine-tolerant infant rats.

Authors:  Dawn C Stoller; Laura J Sim-Selley; Forrest L Smith
Journal:  Brain Res       Date:  2007-01-13       Impact factor: 3.252

8.  Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.

Authors:  Jianren Mao; Backil Sung; Ru-Rong Ji; Grewo Lim
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

9.  Evidence for an important role of protein phosphatases in the mechanism of morphine tolerance.

Authors:  Bichoy H Gabra; Chris P Bailey; Eamonn Kelly; Amanda V Sanders; Graeme Henderson; Forrest L Smith; William L Dewey
Journal:  Brain Res       Date:  2007-05-21       Impact factor: 3.252

10.  A new cytokine: the possible effect pathway of methionine enkephalin.

Authors:  Xin-Hua Liu; Dong-Ai Huang; Fei-Yi Yang; Yan-Sheng Hao; Guo-Guang Du; Ping-Feng Li; Gang Li
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.